Skip to content

Recent Additions in the Treatment of Depressive Disorders

New pharmacologic agents have become available for treating depressive disorders and their placement in therapy has yet to be fully elicited. This information is intended to help the pharmacist in determining where and how these new agents can be most effective.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Summarize the safety and efficacy of the recently approved agents for major depressive disorder, treatment refractory depression, and post-partum depression.
  • Identify the appropriate patients who will benefit from these new therapies,
  • Recognize the expected impact of these newly approved antidepressants in the standard course of treatment for major depressive disorder, treatment refractory depression, and post-partum depression


Michael Angelini, BA, BS, MA, PharmD, BCPP, RPh 
Michael Angelini, BA, BS, MA, PharmD, BCPP, RPh is a Professor of Pharmacy Practice at MCPHS University in Boston, Massachusetts and a Psychiatric Clinical Pharmacist at Saint Luke’s Hospital in New Bedford, MA. He is also a Psychopharmacology Consultant for Commonwealth Pharmacy Services at the University of Massachusetts Medical School. Additionally, he has been a clinical consultant to primary care, community health centers and group homes throughout New England. He has served on faculty positions in the Addiction Fellowship Program at Boston University School of Medicine, the Massachusetts School of Professional Psychology, and Harvard Medical School. Dr. Angelini earned his Master’s degree in Clinical Psychology at Boston University and his Doctor of Pharmacy degree at MCPHS University. Board-certified in Psychiatric Pharmacy, Dr. Angelini has published chapters in therapeutics textbooks, study guides and articles in peer-reviewed journals. Dr. Angelini is a member of the American Association of Colleges of Pharmacy and the Massachusetts Pharmacists Association.


ACPE logo

Release Date: December 4, 2020
Expiration Date: December 7, 2022
Contact Hours: 1.0
Universal Activity Number: 0026-0000-20-207-H01-P | Knowledge-based
ACPE Topic Designator: Disease State Management/Drug Therapy

Registration Fee: Free to MCPHS Alumni and full-time employees; $12.00 for all other professionals.